Loading clinical trials...
Loading clinical trials...
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Conditions
Interventions
Reldesemtiv
Placebo
Locations
64
United States
St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics
Phoenix, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California Irvine
Orange, California, United States
Forbes Norris MDA/ALS Research Center
San Francisco, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
University of Colorado Hospital Anschutz Outpatient Pavilion
Aurora, Colorado, United States
Start Date
July 24, 2017
Primary Completion Date
March 7, 2019
Completion Date
March 7, 2019
Last Updated
September 11, 2020
NCT07322003
NCT07414212
NCT05104710
NCT03233646
NCT07357428
NCT04715399
Lead Sponsor
Cytokinetics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions